Previous 10 | Next 10 |
2024-07-25 08:30:15 ET Palm Beach, FL – July 25, 2024 – The fibromyalgia treatment market has witnessed positive growth trends over the past few years. There is higher disease awareness due to growth in diagnosis rates and growing awareness and concern for this serious, debili...
2024-07-25 07:01:43 ET More on Eli Lilly, Novo Nordisk, etc. Viking Therapeutics, Inc. (VKTX) Q2 2024 Earnings Call Transcript Viking Therapeutics: Great Clinical Results Do Not Guarantee Commercialization Success Viking Therapeutics: Potential Winner In Competitive ...
2024-07-25 07:00:04 ET Summary The Tema Obesity & Cardiometabolic ETF is a new actively managed fund focusing on the obesity treatment market. The investment strategy includes a mix of cash flow-positive companies, high-growth companies, and start-ups with promising technology...
2024-07-25 06:25:00 ET Summary U.S. large cap stocks had a solid second quarter while other market capitalizations and other geographies were more mixed. Performance for the Madison Sustainable Equity Fund (Class Y) was about in line with the S&P 500 during the quarter. Th...
2024-07-25 06:20:00 ET Summary The partnership returned 25.6% gross, 19.7% net of accrued performance fees through June. Broad performance across the market has certainly been respectable, but spectacular performance has generally come from a narrow sliver of Large Cap Growth stoc...
2024-07-24 23:07:14 ET Summary IHE invests in large-cap U.S. pharmaceutical stocks with solid long-term growth outlook but high concentration risk. IHE's fund price has been steady with a positive trend in 2024, but its elevated valuation may not make it a good buy currently. ...
2024-07-24 09:00:00 ET Summary Gilead Sciences has underperformed but is showing potential for growth, with recent positive catalysts starting to drive stock price up. GILD's top-line growth is strong, driven by key drug franchises in HIV, Oncology, and Liver Disease. GILD rem...
2024-07-24 06:39:00 ET If you're a dividend investor, you shouldn't bother with stocks that don't raise their payouts. Inflation has drastically chipped away at consumers' purchasing power in recent years, highlighting just how important it is for dividend income to rise over the long run...
2024-07-24 03:06:53 ET Summary Rigel Pharmaceuticals focuses on innovative therapeutics for hematological conditions and cancers, with FDA-approved products Tavalisse, Rezlidhia, and Gavreto targeting specific diseases. RIGL’s pipeline also includes promising drug candidate...
2024-07-23 19:32:16 ET Summary Sangamo Therapeutics, Inc. is almost out of cash, and as such, at risk of bankruptcy. Therefore, investing in this company is not a good idea for most investors. 3 of its assets have updates coming over the next 1–6 months that could rea...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 07:15:00 ET According to some research, bull markets tend to last an average of 2.6 years. The one we are currently experiencing has been going on for almost two years -- maybe it will soon end, maybe it won't. Equities that can perform well throughout bull runs might be good to ...
2024-07-26 07:45:00 ET Over the last 18 months, the stock market has been incredibly generous to investors. Since January 2023, the S&P 500 has soared 45%, while the tech-heavy Nasdaq Composite has rocketed by 72%. Outside of the technology industry, investors have also foun...
2024-07-25 19:06:06 ET It wasn't so long ago when Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks were flying high thanks to their hotly popular weight loss drugs (Wegovy/Ozempic for Novo Nordisk and Zepbound/Mounjaro for Lilly). In the pharmaceutical industry,...